Project Grant R43DA062438
Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award of $798,828.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The key products and services to be delivered include: The development of an AI platform called M3.AI that will integrate target-based and phenotype-based methodologies to efficiently identify new drug candidates for OUD...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $591,752 Project Grant to Oprems LLC to develop a digital platform for electronic screening to identify the risk of opioid misuse and overdose. The project aims to integrate the tools and processes from Oprems' existing paper-based "ONE (Opioid and Naloxone Education)" program into a tablet-based digital platform. This digital platform will be used to consistently...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $397,829 Project Grant to Callentis Consulting Group LLC, a woman-owned small business in Austin, Texas. The grant, awarded on May 1, 2025, supports the development of an artificial intelligence (AI) platform to discover new therapeutics for substance use disorders. The key products and services to be delivered include: 1) Curated training datasets and machine learning...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop and evaluate an adaptive psychological intervention to improve pain management and reduce opioid use following an injury. The $264,995 grant, awarded on September 15, 2025, will fund the optimization and feasibility testing of a two-part intervention. The first part is a 15-minute computerized brief intervention focused on...
- The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....
- This federal Project Grant award of $144,252 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will fund a research program led by Dr. Carreiro at the University of Massachusetts Medical School (UMMS). The key objectives are to: Develop a novel wearable sensing system called "MINDER" to continuously monitor physiological parameters and use machine learning to accurately identify adherence to buprenorphine treatment for opioid use...
- The U.S. National Institute on Drug Abuse (NIDA) awarded Altrumed LLC a $404,078 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a device-agnostic hypoxia detection software for opioid overdose prediction and positive reversal monitoring. The project, titled "DEVICE-AGNOSTIC HYPOXIA DETECTION SOFTWARE FOR OVERDOSE PREDICTION AND POSITIVE REVERSAL MONITORING," aims to create an innovative wearable sensor system that integrates advanced...
- The National Institute on Drug Abuse (NIDA) awarded Evidation Health, Inc. a $608,046 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a digital product called RESHAPE. The objective of this project is to create a digital platform that addresses the health-related social needs (HRSN) impacting substance use disorder (SUD) recovery. Evidation will conduct formative research, develop, and deploy a new digital experience called RESHAPE to improve...